References
- Myklebust G, Gran JT. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol 1996;35:1161–8.
- Hunder GG. Giant cell arteritis and polymyalgia rheumatica. Med Clin North Am 1997;81:195–219.
- Gran JT. Current therapy of polymyalgia rheumatica. Scand J Rheumatol 1999;28:269–72.
- Delecoeuillerie G, Joly P, Cohen de Lara A, Pagolaggi JB. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis 1988;47: 733–9.
- Myles AB, Perera T, Ridley MG. Prevention of blindness in giant cell arteritis by corticosteroid treatment. Br J Rheumatol 1992;31:103–5.
- Weyand CM, Fulbright JW, Evans JM, Hunder GG, Goronzy JJ. Corticosteroid Requirements in Polymyalgia Rheumatica. Arch Intern Med 1999;159:577–84.
- Evans JM, Hunder GG. Polymyalgia and giant cell arteritis. Clin Rheum Dis 2000;26:493–515.
- Behn AR, Perera T, Myles AB. Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis 1983;42:374–8.
- Gran JT, Myklebust G. The incidence of polymyalgia rheum-atica and temporal arteritis in the county of Aust Agder, South Norway: a prospective study 1987-94. J Rheumatol 1997;24:1739–43.
- Gran JT, Myklebust G. The incidence and clinical character-istics of peripheral arthritis in polymyalgia rheumatica and temporal arteritis: a prospective study of 231 cases. R heumatology 2000;39:283–7.
- Bird HA, Esselinckx W, Dixon ASTJ, Mowat AG, Wood PHN. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 1979;38:434–9.
- Hamrin B. Polymyalgia arterica. Acta Med Scand 1972;Vol 196 Suppl 533:1–13.
- Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis R heum1990;33:1122–8.
- Kirwan JR. Treatment of polymyalgia rheumatica. Br J Rheumatol 1990:24;316–7.
- Andersson R, Malmwall BE, Bengtsson BA. Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand 1986;220:465–9.
- Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis 1988;47:658–61.
- Catoggio LJ, Soriano ER, Imamura PI. Treatment of poly-myalgia rheumatica: lower initial dose. Br J Rheumatol 1991;19:393–4.
- Ayoub WT, Franklin CM, Toreti D. Polymyalgia rheumatica, duration of therapy and long term outcome. Am J Med 1985;79:309–15.
- Kyle V, Hazleman BL. The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 1993;52: 847–50.
- Fauchald R, Rygvold 0, Oystese B. Temporal arteritis and polymyalgia rheumatica. Clinical and biopsy findings. Ann Intern Med 1972;77:845–52.
- Myles AB. Polymyalgia rheumatica and giant cell arteritis : seven year study. Rheumatol Rehabil 1975;14:231–5.
- Lundberg I, Hedfors E. Restricted Dose and Duration of Corticosteroid Treatment in Patients with Polymyalgia Rheumatica and Temporal Arteritis. J Rheumatol 1990;17:1340–5.
- Bahlas S, Ramos-Remus C, Davis P. Clinical outcome of 149 Patients with Polymyalgia Rheumatica and Giant Cell Arteritis. J Rheumatol 1998;25:99–104.
- Gonsalez-Gay MA, Rodriguez-Valverde V, Blanco R, Fernandez-Sueiro JL, Armona J, Figueroa M, et al. Poly-myalgia rheumatica without significantly increased erytrocyte sedimentation rate. A more benign syndrome. Arch Intern Med 1997;157:317–20.
- Helgott SM, Kieval RI. Polymyalgia rheumatica in patients with normal erythrocyte sedimentation rate. Arthritis Rheum 1996;39:304–7.
- Proven A, Gabriel SE, O'Fallon WM, Hunder GG. Polymyalgia Rheumatica with Low Erythrocyte Sedimentation Rate at Diagnosis. J Rheumatol 1999;26:1333–7.